Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ibrutinib works in treating patients with follicular
lymphoma that has come back after a period of improvement or does not respond to treatment.
Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth.